AIM — AIM ImmunoTech Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2019-09-03.
Performance
Technicals
Dividends
Measured signals that fired on AIM
| date | signal | measured base rate |
|---|---|---|
| 2026-05-28 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-05-27 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-05-07 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-04-07 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-03-12 | Equels Thomas K CEO & President | Conversion | 25.0K | 0.00 | 0 |
| 2026-03-12 | CHEMEROW DAVID I. Director | Conversion | 25.0K | 0.00 | 0 |
| 2026-02-05 | CHEMEROW DAVID I. Director | Grant or award | 2.8K | 1.23 | 3.4K |
| 2025-06-13 | Equels Thomas K CEO & President | Open-market purchase | 107 | 7.70 | 824 |
| 2025-06-12 | Equels Thomas K CEO & President | Open-market purchase | 103 | 8.70 | 896 |
| 2025-04-11 | KELLNER TED D Director | Open-market purchase | 2.0M | 0.03 | 59.1K |
| 2025-04-11 | Equels Thomas K CEO & President | Open-market purchase | 2.0M | 0.03 | 59.1K |
| 2025-04-11 | MITCHELL WILLIAM M Director | Open-market purchase | 196.9K | 0.03 | 5.9K |
| 2025-04-04 | Equels Thomas K CEO & President | Open-market purchase | 41.0K | 0.06 | 2.5K |
| 2025-04-04 | Rodino Peter W III COO, Secretary, Gen. Counsel | Open-market purchase | 500 | 0.09 | 45 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 17.5K | 29.9K |
| XTX Topco Ltd | 12.0K | 20.6K |
| JANE STREET GROUP, LLC | 11.7K | 20.0K |
| VANGUARD FIDUCIARY TRUST CO | 10.2K | 17.5K |
| Tower Research Capital LLC (TRC) | 2.7K | 4.7K |
| MORGAN STANLEY | 505 | 864 |
| Community Bank, N.A. | 76 | 132 |
| Virtu Financial LLC | 30 | 50.9K |
| HARBOUR INVESTMENTS, INC. | 19 | 32 |
| CREATIVE FINANCIAL DESIGNS INC /ADV | 18 | 30 |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Aim Immunotech Inc. (AIM) filed form 8-K · 2026-08-11 · SEC EDGAR
- Aim Immunotech Inc. (AIM) filed form 8-K · 2026-08-10 · SEC EDGAR
Others in Healthcare
Ask the AI about AIM
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →